US advocacy groups seldom disclose financial ties to industryBMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d280 (Published 14 January 2011) Cite this as: BMJ 2011;342:d280
- Bob Roehr
- 1Washington, DC
Health advocacy organisations in the United States publicly reported the financial support they get from the drug industry only 25% of the time, says a new study.
The “disease groups,” as they are often called, can be very influential in mobilising the public to support legislation and funding for research and care for the specific condition such as breast cancer or heart disease, says the report, published in the American Journal of Public Health (doi:10.2105/AJPH.2010.300027).
Sheila Rothman, senior author of the study, said that health advocacy groups and drug companies “really advocate for the same things: unrestricted access to all drugs, devices, and diagnostic tools; branded drugs over generics; open formulas over closed ones.”
She added, “They have agendas …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial